Aptevo Therapeutics Inc. (NASDAQ:APVO) Expected to Post Quarterly Sales of $3.40 Million

Equities analysts predict that Aptevo Therapeutics Inc. (NASDAQ:APVO) will announce sales of $3.40 million for the current quarter, Zacks reports. Two analysts have issued estimates for Aptevo Therapeutics’ earnings, with estimates ranging from $3.30 million to $3.50 million. The company is scheduled to report its next earnings results on Friday, February 11th.

On average, analysts expect that Aptevo Therapeutics will report full year sales of $12.03 million for the current financial year, with estimates ranging from $11.93 million to $12.13 million. For the next fiscal year, analysts anticipate that the firm will post sales of $15.90 million, with estimates ranging from $13.80 million to $18.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Aptevo Therapeutics.

A number of equities analysts have recently commented on the company. Zacks Investment Research lowered Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 19th. Roth Capital dropped their price objective on Aptevo Therapeutics from $50.00 to $36.00 and set a “buy” rating on the stock in a research note on Monday, November 15th.

Shares of Aptevo Therapeutics stock traded down $5.08 during trading on Thursday, reaching $11.95. The company’s stock had a trading volume of 24,701,541 shares, compared to its average volume of 901,223. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 0.55. The business’s fifty day moving average price is $14.42 and its 200-day moving average price is $18.89. Aptevo Therapeutics has a one year low of $6.38 and a one year high of $51.75.

In related news, major shareholder Kevin C. Tang sold 369,533 shares of the business’s stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $8.34, for a total transaction of $3,081,905.22. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Kevin C. Tang sold 255,331 shares of the business’s stock in a transaction dated Monday, November 22nd. The shares were sold at an average price of $7.03, for a total value of $1,794,976.93. The disclosure for this sale can be found here. Insiders own 10.88% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Moors & Cabot Inc. bought a new stake in shares of Aptevo Therapeutics in the 3rd quarter valued at approximately $3,729,000. Kennedy Capital Management Inc. bought a new stake in shares of Aptevo Therapeutics in the 2nd quarter valued at approximately $4,217,000. Vanguard Group Inc. grew its stake in shares of Aptevo Therapeutics by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 134,760 shares of the biotechnology company’s stock valued at $3,022,000 after purchasing an additional 3,830 shares during the period. BlackRock Inc. boosted its holdings in shares of Aptevo Therapeutics by 1.9% in the 3rd quarter. BlackRock Inc. now owns 55,394 shares of the biotechnology company’s stock worth $856,000 after acquiring an additional 1,010 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Aptevo Therapeutics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 39,924 shares of the biotechnology company’s stock worth $616,000 after acquiring an additional 1,007 shares in the last quarter. Institutional investors own 96.53% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.

Featured Article: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.